Thrivent Financial for Lutherans Sells 5,044 Shares of Cencora, Inc. $COR

Thrivent Financial for Lutherans cut its position in shares of Cencora, Inc. (NYSE:COR) by 2.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 240,196 shares of the company’s stock after selling 5,044 shares during the period. Thrivent Financial for Lutherans’ holdings in Cencora were worth $81,126,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vestcor Inc increased its position in shares of Cencora by 0.5% during the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after purchasing an additional 28 shares during the period. JFS Wealth Advisors LLC boosted its stake in Cencora by 30.2% in the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after buying an additional 29 shares in the last quarter. Cornerstone Wealth Group LLC boosted its stake in Cencora by 1.3% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after buying an additional 30 shares in the last quarter. Apollon Wealth Management LLC boosted its stake in Cencora by 0.5% in the 4th quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after buying an additional 30 shares in the last quarter. Finally, Vermillion & White Wealth Management Group LLC boosted its stake in Cencora by 31.4% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $43,000 after buying an additional 33 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Cencora stock opened at $256.96 on Friday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The firm has a market cap of $49.99 billion, a P/E ratio of 19.71, a P/E/G ratio of 1.20 and a beta of 0.64. The business’s fifty day moving average is $314.65 and its two-hundred day moving average is $339.22. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts forecast that Cencora, Inc. will post 17.76 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s payout ratio is currently 18.40%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on COR. Morgan Stanley set a $342.00 price target on Cencora in a research note on Friday, May 8th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. William Blair began coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. boosted their price target on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Finally, Wells Fargo & Company decreased their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.